Literature DB >> 16644880

The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer.

D J F Brown1, R Milroy, T Preston, D C McMillan.   

Abstract

BACKGROUND: The Glasgow Prognostic Score (GPS), an inflammation-based prognostic score formed from standard thresholds of C reactive protein (CRP) and albumin, has prognostic value in patients with advanced cancer. Little is known about the general biochemical disturbance associated with the systemic inflammatory response in cancer. AIM: To examine the relationship between the GPS and blood biochemistry in patients with advanced lung and gastrointestinal cancer.
METHODS: The GPS (albumin <35 g/l = 1 and CRP >10 mg/l = 1 combined to form a prognostic score of 0 (normal) and 1 or 2 (abnormal)) and a variety of biochemical variables were examined in patients (n = 50) with advanced lung or gastrointestinal cancer and in a healthy control group (n = 13).
RESULTS: The GPS was normal in all the controls, but abnormal in 78% of the cancer group. Serum levels of sodium, chloride, creatine kinase, zinc and vitamin D were lower in the cancer group (all p<0.01), whereas levels of calcium, copper (both p<0.05), alkaline phosphatase, gamma-glutamyl transferase (both p<0.001) and lactate dehydrogenase (p<0.10) were raised. In the patient group, with increasing GPS, there was a median reduction in Karnofsky Performance Status (25%), haemoglobin (22%), sodium (3%), zinc (15%) and survival (93%, all p<0.05) and a median increase in white cell count (129%), alkaline phosphatase (217%), gamma-glutamyl transferase (371%) and lactate dehydrogenase (130%, all p<0.05). CRP levels were strongly and similarly correlated with alkaline phosphatase and gamma-glutamyl transferase, accounting for more than 25% of the variation in their activities.
CONCLUSION: Several correlations were seen between biochemical variables and increasing GPS. In particular, chronic activation of the systemic inflammatory response in cancer was associated with increase in gamma-glutamyl transferase and alkaline phosphatase activity in patients with advanced lung and gastrointestinal cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644880      PMCID: PMC1955069          DOI: 10.1136/jcp.2005.033217

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  15 in total

1.  Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss.

Authors:  D C McMillan; W S Watson; P O'Gorman; T Preston; H R Scott; C S McArdle
Journal:  Nutr Cancer       Date:  2001       Impact factor: 2.900

2.  Prognostic factors in advanced gastrointestinal cancer patients with weight loss.

Authors:  P O'Gorman; D C McMillan; C S McArdle
Journal:  Nutr Cancer       Date:  2000       Impact factor: 2.900

3.  Changes in micronutrient concentrations following anti-inflammatory treatment in patients with gastrointestinal cancer.

Authors:  D C McMillan; N Sattar; D Talwar; D S O'Reilly; C S McArdle
Journal:  Nutrition       Date:  2000-06       Impact factor: 4.008

4.  Clinical survival predictors in patients with advanced cancer.

Authors:  A Viganó; E Bruera; G S Jhangri; S C Newman; A L Fields; M E Suarez-Almazor
Journal:  Arch Intern Med       Date:  2000-03-27

5.  Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer.

Authors:  P O'Gorman; D C McMillan; C S McArdle
Journal:  Nutr Cancer       Date:  1999       Impact factor: 2.900

Review 6.  The role of C-reactive protein as a prognostic indicator in advanced cancer.

Authors:  Fade Aziz Mahmoud; Nilo I Rivera
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

7.  Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer.

Authors:  Maqsood M Elahi; Donald C McMillan; Colin S McArdle; Wilson J Angerson; Naveed Sattar
Journal:  Nutr Cancer       Date:  2004       Impact factor: 2.900

8.  A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer.

Authors:  L M Forrest; D C McMillan; C S McArdle; W J Angerson; K Dagg; H R Scott
Journal:  Br J Cancer       Date:  2005-05-23       Impact factor: 7.640

9.  The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer.

Authors:  E Bromwich; D C McMillan; G W A Lamb; P A Vasey; M Aitchison
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

10.  The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer.

Authors:  H R Scott; D C McMillan; L M Forrest; D J F Brown; C S McArdle; R Milroy
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

View more
  36 in total

Review 1.  Does vitamin D affect risk of developing autoimmune disease?: a systematic review.

Authors:  Martin A Kriegel; JoAnn E Manson; Karen H Costenbader
Journal:  Semin Arthritis Rheum       Date:  2010-11-02       Impact factor: 5.532

2.  Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.

Authors:  Anna Song; Wankyu Eo; Sookyung Lee
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

3.  Usefulness of an inflammation-based prognostic score (mGPS) for predicting survival in patients with unresectable malignant biliary obstruction.

Authors:  Yoshimi Iwasaki; Mitsuru Ishizuka; Masato Kato; Junji Kita; Mitsugi Shimoda; Keiichi Kubota
Journal:  World J Surg       Date:  2013-09       Impact factor: 3.352

4.  Prognostic significance of preoperative fibrinogen in patients with colon cancer.

Authors:  Zhen-Qiang Sun; Xiao-Na Han; Hai-Jiang Wang; Yong Tang; Ze-Liang Zhao; Yan-Li Qu; Rui-Wei Xu; Yan-Yan Liu; Xian-Bo Yu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

5.  Vitamin D depletion: of clinical significance in advanced cancer?

Authors:  Carol A Stone; Rose Anne Kenny; Martin Healy; J Bernard Walsh; Peter G Lawlor
Journal:  Support Care Cancer       Date:  2011-02-18       Impact factor: 3.603

6.  Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer.

Authors:  Tsutomu Namikawa; Nobuko Ishida; Sachi Tsuda; Kazune Fujisawa; Eri Munekage; Jun Iwabu; Masaya Munekage; Sunao Uemura; Shigehiro Tsujii; Takahiko Tamura; Tomoaki Yatabe; Hiromichi Maeda; Hiroyuki Kitagawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Gastric Cancer       Date:  2018-11-11       Impact factor: 7.370

7.  Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.

Authors:  Justin D Blasberg; Harvey I Pass; Chandra M Goparaju; Raja M Flores; Suzie Lee; Jessica S Donington
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

8.  The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study.

Authors:  M J Proctor; D Talwar; S M Balmar; D S J O'Reilly; A K Foulis; P G Horgan; D S Morrison; D C McMillan
Journal:  Br J Cancer       Date:  2010-08-17       Impact factor: 7.640

9.  Construction of a new, objective prognostic score for terminally ill cancer patients: a multicenter study.

Authors:  Sang-Yeon Suh; Youn Seon Choi; Jae Yong Shim; Young Sung Kim; Chang Hwan Yeom; Daeyoung Kim; Shin Ae Park; Sooa Kim; Ji Yeon Seo; Su Hyun Kim; Daegyeun Kim; Sung-Eun Choi; Hong-Yup Ahn
Journal:  Support Care Cancer       Date:  2009-04-21       Impact factor: 3.603

10.  Prognostic significance of Glasgow prognostic score in patients with stage II colorectal cancer.

Authors:  Mao-Song Lin; Jun-Xing Huang; Hong Yu
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.